Literature DB >> 1717669

Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.

H R Maxon1, L E Schroder, V S Hertzberg, S R Thomas, E E Englaro, R Samaratunga, H Smith, J S Moulton, C C Williams, G J Ehrhardt.   

Abstract

Rhenium-186 (tin) hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that simultaneously localizes in multiple skeletal metastases in patients with advanced cancer. A single intravenous administration of 30-35 mCi (1110-1295 MBq) is associated with a prompt, significant relief of osseous pain in about 80% of such patients. The efficacy of this new compound was evaluated further by utilizing a double-blind crossover comparison with 99mTc-methylene diphosphonate (MDP) as a radioactive placebo. The new rhenium compound resulted in a significantly (p less than 0.05) greater decrease in pain than did treatment with the radioactive placebo. Rhenium-186(Sn)HEDP appears to be a useful new compound for the palliation of painful skeletal metastases.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1717669

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


  25 in total

1.  Bisphosphonates in metastatic prostate cancer.

Authors:  Masood A Khan; Alan W Partin
Journal:  Rev Urol       Date:  2003

Review 2.  WITHDRAWN: Radiotherapy for the palliation of painful bone metastases.

Authors:  Henry J McQuay; Sally L Collins; Dawn Carroll; R Andrew Moore; Sheena Derry
Journal:  Cochrane Database Syst Rev       Date:  2013-11-22

3.  Solitary painful osseous metastases: correlation of imaging features with pain palliation after radiofrequency ablation--a multicenter american college of radiology imaging network study.

Authors:  Jeffrey P Guenette; Michael J Lopez; Eunhee Kim; Damian E Dupuy
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

Review 4.  Targeted radionuclide therapy for bone metastases.

Authors:  V J Lewington
Journal:  Eur J Nucl Med       Date:  1993-01

Review 5.  Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals.

Authors:  Joon Young Choi
Journal:  Nucl Med Mol Imaging       Date:  2018-01-12

6.  Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies.

Authors:  M A Plaizier; J C Roos; G J Teule; E B van Dieren; W den Hollander; H J Haisma; R L DeJager; A van Lingen
Journal:  Eur J Nucl Med       Date:  1994-03

7.  A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.

Authors:  J M O'Sullivan; A R Norman; V R McCready; G Flux; F M Buffa; B Johnson; J Coffey; G Cook; J Treleaven; A Horwich; R A Huddart; C C Parker; D P Dearnaley
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

8.  Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors:  W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal:  Eur J Nucl Med       Date:  1997-06

Review 9.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 10.  Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research.

Authors:  J J Body
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.